Journal Mobile Options
Table of Contents
Vol. 11, No. 4, 2008
Issue release date: April 2008

Strategies and Stakeholders: Minority Recruitment in Cancer Genetics Research

James R.D. · Yu J.-H. · Henrikson N.B. · Bowen D.J. · Fullerton S.M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

The Cancer Genetics Network (CGN) is one of a growing number of large-scale registries designed to facilitate investigation of genetic and environmental contributions to health and disease. Despite compelling scientific and social justice arguments that recommend diverse participation in biomedical research, members of ethnic minority groups continue to be chronically underrepresented in such projects. The CGN studies reported in this issue used strategies well documented to increase minority participation in research activities, including use of community-targeted materials, addressing community trust concerns, and the adoption of personalized and flexible research protocols. Here, we review the outcome of these efforts to increase minority recruitment to the CGN, and ask what lessons the findings suggest for future minority recruitment initiatives.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Anton-Culver H, Ziogas A, Bowen D, Finkelstein D, Griffin C, Hanson J, Isaacs C, Kasten-Sportes C, Mineau G, Nadkarni P, Rimer B, Schildkraut J, Strong L, Weber B, Winn D, Hiatt R, Nayfield S: The Cancer Genetics Network: recruitment results and pilot studies. Community Genet 2003;6:171–177.
  2. Austin MA, Harding S, McElroy C: Genebanks: a comparison of eight proposed international genetic databases. Community Genet 2003;6:37–45.
  3. Hakonarson H, Gulcher JR, Stefansson K: deCODE genetics, Inc. Pharmacogenomics 2003;4:209–215.
  4. Senior K: UK Biobank launched to mixed reception. Lancet Neurol 2006;5:390.
  5. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S: Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med 1999;14:537–546.
  6. Moorman PG, Skinner CS, Evans JP, Newman B, Sorenson JR, Calingaert B, Susswein L, Crankshaw TS, Hoyo C, Schildkraut JM: Racial differences in enrolment in a cancer genetics registry. Cancer Epidemiol Biomarkers Prev 2004;13:1349–1354.
  7. Shavers-Hornaday VL, Lynch CF, Burmeister LF, Torner JC: Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health 1997;2:31–45.
  8. Swanson GM, Ward AJ: Recruiting minorities into clinical trials: toward a participant-friendly system. J Natl Cancer Inst 1995;87:1747–1759.
  9. Rebbeck TR, Halbert CH, Sankar P: Genetics, epidemiology, and cancer disparities: is it black and white? J Clin Oncol 2006;24:2164–2169.
  10. Hall MJ, Olopade OI: Disparities in genetic testing: thinking outside the BRCA box. J Clin Oncol 2006;24:2197–2203.
  11. Burchard EG, Ziv E, Coyle N, Gomez SL, Tang H, Karter AJ, Mountain JL, Perez-Stable EJ, Sheppard D, Risch N: The importance of race and ethnic background in biomedical research and clinical practice. N Engl J Med 2003;348:1170–1175.
  12. Morrison A, Levy R: Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes. Pharmacogenomics 2004;5:673–689.
  13. Perera FP: Environment and cancer: who are susceptible? Science 1997;278:1068–1073.
  14. Maitland ML, DiRienzo A, Ratain MJ: Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol 2006;24:2151–2157.
  15. Underwood SM: Minorities, women, and clinical cancer research: the charge, promise, and challenge. Ann Epidemiol 2000;10:S3–S12.
  16. Wood AJ: Racial differences in the response to drugs: pointers to genetic differences. N Engl J Med 2001;344:1394–1396.
  17. Nanda R, Schumm LP, Cummings S, Fackenthal JD, Sveen L, Ademuyiwa F, Cobleigh M, Esserman L, Lindor NM, Neuhausen SL, Olopade OI: Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry. JAMA 2005;294:1925–1933.
  18. Corbie-Smith G, Miller WC, Ransohoff DF: Interpretations of ‘appropriate’ minority inclusion in clinical research. Am J Med 2004;116:249–252.
  19. National Institutes of Health: NIH Policy and Guidelines on the Inclusion of Women and Minorities as Subjects in Clinical Research – Amended, October, 2001. http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.html. Accessed March 1, 2005.
  20. Djomand G, Katzman J, di Tommaso D, Hudgens MG, Counts GW, Koblin BA, Sullivan PS: Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002. Public Health Rep 2005;120:543–548.
  21. Hussain-Gambles M, Atkin K, Leese B: Why ethnic minority groups are under-represented in clinical trials: a review of the literature. Health Soc Care Community 2004;12:382–388.
  22. Shavers VL, Fagan P, Lawrence D, McCaskill-Stevens W, McDonald P, Browne D, McLinden D, Christian M, Trimble E: Barriers to racial/ethnic minority application and competition for NIH research funding. J Natl Med Assoc 2005;97:1063–1077.

    External Resources

  23. Brandon DT, Isaac LA, LaVeist TA: The legacy of Tuskegee and trust in medical care: is Tuskegee responsible for race differences in mistrust of medical care? J Natl Med Assoc 2005;97:951–956.
  24. Shavers VL, Lynch CF, Burmeister LF: Racial differences in factors that influence the willingness to participate in medical research studies. Ann Epidemiol 2002;12:248–256.
  25. Dalton R: When Two Tribes Go to War. Nature 2004;430:500–502.
  26. Beard B: Havasupais get support in research suit: say ASU used blood samples for more than diabetes. Arizona Republic, 2006.
  27. Mitchell TL, Baker E: Community-building versus career-building research: the challenges, risks, and responsibilities of conducting research with Aboriginal and Native American communities. J Cancer Educ 2005;20:41–46.
  28. Shavers VL, Lynch CF, Burmeister LF: Factors that influence African-Americans’ willingness to participate in medical research studies. Cancer 2001;91:233–236.
  29. Armstrong K, Calzone K, Stopfer J, Fitzgerald G, Coyne J, Weber B: Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2000;9:1251–1254.
  30. Hughes C, Peterson SK, Ramirez A, Gallion KJ, McDonald PG, Skinner CS, Bowen D: Minority recruitment in hereditary breast cancer research. Cancer Epidemiol Biomarkers Prev 2004;13:1146–1155.
  31. Adderley-Kelly B, Green PM: Strategies for successful conduct of research with low-income African American populations. Nurs Outlook 2005;53:147–152.
  32. Fisher PA, Ball TJ: Tribal participatory research: mechanisms of a collaborative model. Am J Community Psychol 2003;32:207–216.
  33. Israel BA, Parker EA, Rowe Z, Salvatore A, Minkler M, Lopez J, Butz A, Mosley A, Coates L, Lambert G, Potito PA, Brenner B, Rivera M, Romero H, Thompson B, Coronado G, Halstead S: Community-based participatory research: lessons learned from the Centers for Children’s Environmental Health and Disease Prevention Research. Environ Health Perspect 2005;113:1463–1471.
  34. O’Neil J, Elias B, Wastesicoot J: Building a health research relationship between First Nations and the University in Manitoba. Can J Public Health 2005;96(suppl 1):S9–S12.

    External Resources

  35. Brugge D, Missaghian M: Protecting the Navajo People through tribal regulation of research. Sci Eng Ethics 2006;12:491–507.
  36. Christopher S: Recommendations for conducting successful research with Native Americans. J Cancer Educ 2005;20:47–51.
  37. Quigley D: A review of improved ethical practices in environmental and public health research: case examples from native communities. Health Educ Behav 2006;33:130–147.
  38. Weijer C: Benefit-sharing and other protections for communities in genetic research. Clin Genet 2000;58:367–368.
  39. Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, Gooding R, DeWitty RL: Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 2004;22:730–734.
  40. Catz DS, Green NS, Tobin JN, Lloyd-Puryear MA, Kyler P, Umemoto A, Cernoch J, Brown R, Wolman F: Attitudes about genetics in underserved, culturally diverse populations. Community Genet 2005;8:161–172.
  41. Hendrickson SG: Video recruitment of non-English-speaking participants. West J Nurs Res 2007;29:232–242.
  42. Burhansstipanov L, Krebs LU, Grass R, Wanliss EJ, Saslow D: A review of effective strategies for native women’s breast health outreach and education. J Cancer Educ 2005;20:71–79.
  43. Satia JA, Galanko JA, Rimer BK: Methods and strategies to recruit African Americans into cancer prevention surveillance studies. Cancer Epidemiol Biomarkers Prev 2005;14:718–721.
  44. Yancey AK, Ortega AN, Kumanyika SK: Effective recruitment and retention of minority research participants. Annu Rev Public Health 2006;27:1–28.
  45. Lemke AA, Dayal S, Geibel LJ: Preconception genetic counseling: three years of experience at a community-based health center. J Genet Couns 1998;7:71–85.

    External Resources

  46. McCaskill-Stevens W, Pinto H, Marcus AC, Comis R, Morgan R, Plomer K, Schoentgen S: Recruiting minority cancer patients into cancer clinical trials: a pilot project involving the Eastern Cooperative Oncology Group and the National Medical Association. J Clin Oncol 1999;17:1029–1039.
  47. Moorman PG, Newman B, Millikan RC, Tse CK, Sandler DP: Participation rates in a case-control study: the impact of age, race, and race of interviewer. Ann Epidemiol 1999;9:188–195.
  48. Butterfoss FD: Process evaluation for community participation. Annu Rev Public Health 2006;27:323–340.
  49. Glasgow RE, Klesges LM, Dzewaltowski DA, Bull SS, Estabrooks P: The future of health behavior change research: what is needed to improve translation of research into health promotion practice? Ann Behav Med 2004;27:3–12.
  50. Brown DR, Topcu M: Willingness to participate in clinical treatment research among older African Americans and Whites. Gerontologist 2003;43:62–72.
  51. Messer L, Steckler A, Dignan M: Early detection of cervical cancer among Native American women: a qualitative supplement to a quantitative study. Health Educ Behav 1999;26:547–562.
  52. Aitken L, Gallagher R, Madronio C: Principles of recruitment and retention in clinical trials. Int J Nurs Pract 2003;9:338–346.
  53. Orians CE, Erb J, Kenyon KL, Lantz PM, Liebow EB, Joe JR, Burhansstipanov L: Public education strategies for delivering breast and cervical cancer screening in American Indian and Alaska Native populations. J Public Health Manag Pract 2004;10:46–53.

    External Resources

  54. Halbert CH, Gandy OH Jr, Collier A, Shaker L: Intentions to participate in genetics research among African American smokers. Cancer Epidemiol Biomarkers Prev 2006;15:150–153.
  55. Fouad MN, Partridge E, Green BL, Kohler C, Wynn T, Nagy S, Churchill S: Minority recruitment in clinical trials: a conference at Tuskegee, researchers and the community. Ann Epidemiol 2000;10:S35–S40.
  56. Burhansstipanov L, Bemis L, Kaur JS, Bemis G: Sample genetic policy language for research conducted with native communities. J Cancer Educ 2005;20:52–57.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50